Skip to main content
Premium Trial:

Request an Annual Quote

RXi Begins Phase I Trial of Anti-Scarring Drug Candidate

Premium

RXi Pharmaceuticals said this week that it has begun a phase I trial of its anti-scarring compound RXI-109, marking the start of the company's first ever clinical trial.

RXI-109 uses the company's so-called self-delivering RNAi technology to inhibit connective tissue growth factor, a protein linked to wound healing and other fibrotic processes. The phase I study is examining the compound in surgical patients.

Since it was spun out of CytRx in 2007, RXi has on several occasions failed to meet publicly stated guidance on the start of clinical studies for its various drug candidates. Recently appointed CEO Geert Cauwenbergh, however, told Gene Silencing News last month that he had made the RXI-109 phase I trial a priority (GSN 5/17/2012).

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.